Dupilumab in Children Under 6 Years With Moderate‐to‐Severe Atopic Dermatitis: A 16‐Week Real‐World Prospective Study on Efficacy, Safety, and Local‐Systemic Immune Responses
Short-term dupilumab exhibited favorable outcomes in young children with AD, primarily through the remodeling of CLA<sup>+</sup>Th2 cells and the restoration of skin barrier functions. Although circulating Th2 inflammation was not completely normalized within a 16-week period, the significant reductions in TARC and MDC indicate systemic improvement and underscore the importance of maintenance therapy.
Authors
- Qing‐Qing Tan (ORCID: https://orcid.org/0000-0002-3858-0528)
- Yunxuan Zhang (ORCID: https://orcid.org/0009-0009-3303-2512)
- Huan Yang (ORCID: https://orcid.org/0000-0002-6921-8791)
- Xiaoyan Luo (ORCID: https://orcid.org/0000-0002-1786-5487)
- Xiaoying Zhou (ORCID: https://orcid.org/0000-0003-3298-5089)
- Lingling Wang (ORCID: https://orcid.org/0000-0003-0272-2974)
- Jingsi Chen (ORCID: https://orcid.org/0000-0001-5189-8891)
- Hua Wang (ORCID: https://orcid.org/0000-0001-5938-0851)
- Jie Jiang
- Jiangshan Pi
Institutions
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Allergy
- Published
- 2025-10-07
- DOI
- https://doi.org/10.1111/all.70090
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00